UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2023
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes ☐ No
☒
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published
one announcement (the “Public Notices”) to the Australian Securities Exchange on June 30, 2023 titled:
|
- |
“Immuron Chairman Transition” |
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
IMMURON LIMITED |
|
|
|
|
|
|
|
|
Date: June 30, 2023 |
By: |
/s/ Phillip Hains |
|
|
Phillip Hains |
|
|
Company Secretary |
Exhibit 99.1
Immuron Chairman
Transition
Melbourne, Australia, June 30, 2023: Immuron Limited
(ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the transition
of Paul Brennan from Non-Executive Director to Chairman, effective July 1, 2023. Dr Roger Aston will continue on the Board, transitioning
from Chairman to Non-Executive Director.
The Board determined that, having successfully
steered the Company to US Food and Drug Administration (FDA) approval of two Investigational New Drug Applications (IND) for IMM-124E
(Travelan®) and CampETEC (Campylobacter and enterotoxigenic Escherichia coli), the time was now right for Paul Brennan to transition
to the role of Chairman as the Company progresses, in parallel, to further commercial development of our lead candidates and a commitment
to pursue organic and M&A growth strategies. Immuron is focusing on increasing penetration of existing products in existing markets
while seeking to increase product offering, market geographies and sales channels to drive revenue growth and ultimately shareholder value.
CEO Steven Lydeamore said, “On behalf of
the entire team at Immuron, I would like to acknowledge Roger’s significant contribution to the Company as Chairman over the past
eleven years. His transition to a Non-Executive Director role ensures we will continue to benefit from Roger’s guidance as Phase
2 trials progress for our lead candidates.
Mr Brennan joined Immuron as a Non-Executive Director
in March 2022, and has extensive experience in the health system through his clinical background and commercial exposure with various
multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for seven years from 2015 to 2021
and took the company from a market capitalisation of $30M to a high of $2B. Prior to this Mr Brennan was Marketing Director Australia
and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare for six years.
Commenting on his appointment as Chairman, Mr
Brennan said: “I am looking forward to the Chairman appointment at such a pivotal time for Immuron, with the Company having made
significant progress in utilising its proprietary technology platform to develop a novel class for orally delivered polyclonal antibodies
for the treatment of infectious diseases, and with the Company recently implementing its plan to realise the full potential of its commercial
product, Travelan®.”
“I am excited to support and work with Steven
to drive the business towards achievement of its strategic objectives. In the next twelve months the Company anticipates significant milestones
including completion of at least two clinical trials and FDA submission of an IND for IMM-529 for Clostridioides difficile (CDI). CDI
can cause life-threatening diarrhoea and is the leading healthcare-related gastrointestinal infection in the world. The global CDI market
was estimated to increase to $1.7B by 2026 according to a report by GlobalData.1 As international travel continues to increase
and the Company implements its strategies to increase market penetration and market expansion, strong revenue growth is anticipated to
continue into FY24.”
This release has been authorised by the directors
of Immuron Limited.
- - - END - - -
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
steve@immuron.com
About Travelan®
Travelan® is an
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a
digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly
purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan®
is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’
Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed
natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan®
is sold as a dietary supplement for digestive tract protection.
About Travelers’ diarrhea
Travelers’ diarrhea
is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,
and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with travelers’ diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
About Immuron
Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases.
For more information
visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Immuron (NASDAQ:IMRN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immuron (NASDAQ:IMRN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024